We are tremendously excited and honored to be in a position to offer clinical labs and health systems this pioneering technology integrated within Tute’s cloud-based genome informatics solution.

I’m going to assume you’re familiar with the world of genome sequencing. Why? Because I already wrote an article about Tute Genomics and CEO Reid Robison, where he was kind enough to explain all the delicate nuances of the genetic world. If you haven’t read it, do so now, or else you this will all sound like garbled nonsense and I will lose a vast amount of respect for you as a Beehive Startups reader, knowledge-seeker, and human being.

Now that you’re up-to-date on Tute Genomics and their mission, here’s the big news — Tute has acquired Knome, a human genome interpretation company founded by geneticist/Harvard professor George Church and boasting the technology of knoSYS, the highest-class genome interpretation/clinical support system on the market.

“Knome’s software is a testament to the extraordinary foresight and ingenuity of its scientists and engineers, as well as the remarkable amount of financial support the company has achieved over the years,” Robison said in a statement. “The result is a wealth of technology assets that are well-poised to tackle the bioinformatics challenges faced by healthcare, such as rapidly processing raw genome sequencing data, performing clinical interpretation of the data and generating actionable clinical reports. We are tremendously excited and honored to be in a position to offer clinical labs and health systems this pioneering technology integrated within Tute’s cloud-based genome informatics solution.”

A busy year for Tute Genomics gets busier — a sharing partnership with Google Genomics in March, a $3.9M funding round in June, and now the acquisition of Knome and all of its genetic goodness. A world with personalized medicine is creeping ever closer.

Published 11/2/2015